Early-stage TNBC: ixabepilone safer, as effective as paclitaxel

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • In patients with early-stage triple-negative breast cancer (TNBC), the microtubule stabilizer ixabepilone (Ixempra) is safer and as effective as paclitaxel (Taxol) in combination with AC (doxorubicin [Adriamycin]/cyclophosphamide [Cytoxan]).

Why this matters

 

 

  • Ixabepilone offers a treatment alternative to paclitaxel for early-stage TNBC.

Study design

 

 

  • This was a phase 3 randomized controlled trial in which 614 patients who completed surgery were randomly assigned to 4 cycles of AC followed by either 4 cycles of ixabepilone (n=306) or paclitaxel (n=308).
  • Patients were followed for a median of 48 mo.
  • Funding: Bristol-Myers Squibb.

Key results

 

 

  • Ixabepilone had similar 5-y DFS (87.1%; 95% CI, 82.6%-90.5%) as paclitaxel (84.7%; 95% CI, 79.7%-88.6%).
  • Ixabepilone had similar 5-y OS (89.7%; 95% CI, 85.5%-92.7%) as paclitaxel (89.6%; 95% CI, 85.0%-92.9%).
  • Paclitaxel had more frequent treatment discontinuation, dose modifications, and overall peripheral neuropathy.

Limitations

 

 

  • None identified.